Skip to main content

Immune Niches for Cancer ImmunoTherapy Enhancement

Objective

Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in the 21st century. Immunotherapy of cancer by checkpoint inhibitors, vaccines or adoptive T cell therapy is coming of age and has the potential to cure cancer, but is still hampered by some major limitations. For instance, Adoptive Cell Therapy (ACT) with unmanipulated or engineered T cells (TCR-transgenic and CAR-T cells) has indeed demonstrated success in the treatment of patients affected by leukemias, but is much less effective against lymphomas and solid tumors. One likely explanation is that we do not educate the right type of anti-tumor T cells. The T cells considered to be the gold standard for tumor therapy have stem cell memory features, but the proper and safe way to generate these fit T cells for clinical purposes is still an unresolved matter. Here we propose an advanced transformative technology termed INCITE, utilizing a novel high-resolution 3D microfabrication technology to engineer a specially tailored microenvironment that will be inhabited by cells central for T cells education in order to generate the fittest anti-tumor T cells for advanced adoptive T cell therapy. INCITE will bring together a transdisciplinary consortium capable of developing this innovative platform by combining state-of-the-art 3D printing, computer modeling, bioengineering, bioinformatics, immunology, developmental and cancer biology approaches, toward the development of a functional immune niche for selection and expansion of tumor-rejecting T cells. The INCITE platform will revolutionize the treatment of cancer patients with ACT, with a profound impact on the quality of life and well-being of millions of people.

Call for proposal

H2020-FETOPEN-2018-2019-2020-01
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU
Address
Hogskoleringen 1
7491 Trondheim
Norway
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 710 000

Participants (7)

UPNANO GMBH
Austria
EU contribution
€ 647 500
Address
Modecenterstrasse 22, D36
1030 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TECHNISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 239 365
Address
Karlsplatz 13
1040 Wien
Activity type
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
EU contribution
€ 462 540
Address
Christoph Probst Platz 1
6020 Innsbruck
Activity type
Higher or Secondary Education Establishments
OSPEDALE SAN RAFFAELE SRL
Italy
EU contribution
€ 829 750
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
DE DUVE INSTITUTE AISBL
Belgium
EU contribution
€ 381 500
Address
Avenue Hippocrate 75/50
1200 Bruxelles
Activity type
Research Organisations
STIFTUNG REGENSBURGER CENTRUM FUR INTERVENTIONELLE IMMUNOLOGIE
Germany
EU contribution
€ 389 135
Address
Franz Josef Strauss Allee 11
93053 Regensburg
Activity type
Research Organisations
BOUKJE.COM CONSULTING BV
Netherlands
EU contribution
€ 338 875
Address
Bulkemstraat 4A
6369 XW Simpelveld
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)